Current and emerging treatment options in chronic myeloid leukemia
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - Cancer, 2007 - Wiley Online Library
Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
Current and emerging treatment options in chronic myeloid leukemia
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - Cancer, 2007 - pubmed.ncbi.nlm.nih.gov
Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
[引用][C] Current and emerging treatment options in chronic myeloid leukemia
E JABBOUR - Cancer, 2007 - cir.nii.ac.jp
[PDF][PDF] Current and Emerging Treatment Options in Chronic Myeloid Leukemia
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - CANCER, 2007 - Citeseer
Chronic myeloid leukemia (CML) is one of the most extensively studied and, arguably, best
understood neoplasms. 1–4 Approximately 4500 new cases of CML are diagnosed in the …
understood neoplasms. 1–4 Approximately 4500 new cases of CML are diagnosed in the …
Current and emerging treatment options in chronic myeloid leukemia
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - …, 2007 - mdanderson.elsevierpure.com
Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
Current and emerging treatment options in chronic myeloid leukemia
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - …, 2007 - augusta.elsevierpure.com
Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
Current and emerging treatment options in chronic myeloid leukemia
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - …, 2007 - scholars.northwestern.edu
Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
[引用][C] Current and emerging treatment options in chronic myeloid leukemia
E JABBOUR, JE CORTES, FJ GILES, S O'BRIEN… - Cancer, 2007 - pascal-francis.inist.fr
Current and emerging treatment options in chronic myeloid leukemia CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Current and emerging treatment options in chronic myeloid leukemia.
E Jabbour, JE Cortes, FJ Giles, S O'Brien… - Cancer, 2007 - europepmc.org
Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …
[引用][C] Current and emerging treatment options in chronic myeloid leukemia
E JABBOUR - Cancer, 2007 - cir.nii.ac.jp
Current and emerging treatment options in chronic myeloid leukemia | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …